Similar Items: Currently Available Biomarkers and Strategies for the Validation of Novel Candidates for Neurochemical Dementia Diagnostics in Alzheimer’s Disease and Mild Cognitive Impairment
- A potential multimodal biomarker – cognitive signature associated with the conversion from subjective cognitive decline to mild cognitive impairment
- Vascular cognitive impairment and dementia drug‐development pipeline 2025
- Refining cognitive dispersion metrics for brain–behavior prediction in aging and mild cognitive impairment
- Virtual reality-based cognitive assessment tools for mild cognitive impairment screening: comparison with traditional paper-and-pencil-based cognitive assessment tools
- Mid‐ and late‐life depression increases risk of Alzheimer's disease and related dementias in veterans
- CSF Biomarkers of Alzheimer’s Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design